Davide Matino at BIC 2025: Phase 3 Data on Fitelparvovec for Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Updated Ph3 data on gene therapy for haemophilia A with giroctocogene fitelparvovec (AAV6, 3e13 vg/kg in 74 participants), presented by Davide Matino at BIC meeting 2025:
~35% of participants maintained near-normal to normal FVIII activity (40–150%) at 2 years post-infusion
Durability data is impressive: sustained efficacy approaches three years of follow-up, demonstrating the transformative potential of this AAV6 approach
- Slow decline pattern:
– Year 1 mean: 51.7%
– Year 2 mean: 51.9% (stabilization)
– Year 3 mean: 40.7% (median: 38.0%)
Note: Only 8 participants had 3-year follow-up
- Sustained FVIII levels >5% in >80% of participants at 15 and at 24 months
- 98.3% reduction in treated bleeding episodes (4.08 → 0.07 ABR post-infusion)
- Transient FVIII activity >150% in nearly 50%, managed with low-dose prophylactic DOAC in 30%
- One participant developed a thrombotic event (history of thrombosis and risk factors)
- 2 participants resumed FVIII prophylaxis
Generally well-tolerated safety profile with manageable ALT elevations (ALT ↑ in 61%)
High rate of infusion-related reactions (75%), but no discontinuation of study drug administration
One case of new cancer at 35 months (oral SCC, not related to study drug); in total 2 malignancies reported
One case of FVIII inhibitor development (more to follow tomorrow!)
Despite these results, Pfizer has discontinued this program and terminated their collaboration with Sangamo Therapeutics in December 2024”
More from BIC 2025 featured in Hemostasis Today.
-
Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
-
Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
-
Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
-
Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
-
Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
-
Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry